Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Filgrastim
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Amneal Completes Acquisition of Kashiv Specialty Pharmaceuticals
Details : Amneal Pharmaceuticals has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and no...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 05, 2021
Lead Product(s) : Filgrastim
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Amneal Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : K102
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Amneal Pharmaceuticals
Deal Size : $108.0 million
Deal Type : Acquisition
Amneal to Acquire Substantially all of Kashiv Specialty Pharmaceuticals
Details : The acquisition enhances Amneal's R&D expertise with the addition of the Kashiv Specialty team and its impressive track record in developing complex generic products (e.g. Yuvafem and EluRyng) and innovative drug delivery technologies.
Brand Name : K102
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 12, 2021
Lead Product(s) : K102
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Amneal Pharmaceuticals
Deal Size : $108.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?